Fenoldopam mesylate, a selective dopamine receptor D1 agonist.
Induces vasodilatation of the renal, mesenteric, peripheral and coronary arteries.
Trade name Corlopam
Hepatic metabolism and CYP is not involved.
Has a half-life of 5 minutes.
Excretion 90% renal and 10% fecal.
A synthetic benzazepine which acts as a selective D1 receptor partial agonist antihypertensive agent.
Used as an antihypertensive agent postoperatively.
Used to treat a hypertensive crisis.
The only intravenous agent that improves renal perfusion.
Causes arterial vasodilation leading to a decrease in blood pressure by activating peripheral D1receptors.
Promotes sodium excretion via specific dopamine receptors along the nephron.
No effect on beta adrenoceptors.
D1 receptor stimulation activates adenylyl cyclase and raises intracellular cyclic AMP, resulting in vasodilation of most arterial beds, including renal, mesenteric, and coronary arteries.
Reduces in systemic vascular resistance.
Has a rapid onset of action of 4 minutes) and short duration of action of <10 minutes.
Adverse reactions include: headache, flushing, nausea, hypotension, reflex tachycardia, and increased intraocular pressure.
Contains sodium metabisulfite, a sulfite that may rarely cause allergic-type reactions including anaphylactic symptoms and asthma in susceptible people.
Used with caution to patients with glaucoma or raised intraocular pressure as it raises intraocular pressure.
Concomitant use with a beta-blocker should be avoided if possible, as unexpected hypotension can result from beta-blocker inhibition of sympathetic-mediated reflex tachycardia in response to fenoldopam